• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Pregabalin Dexcel
    / Dexcel


    Active Ingredient
    Pregabalin 25 mg, 50 mg, 75 mg, 100 mg, 150mg, 200 mg, 225 mg, 300 mg

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Capsules

    56 X 25 mg

    partial basket chart 58328

    Capsules

    56 X 50 mg

    partial basket chart 58329

    Capsules

    56 X 75 mg

    partial basket chart 58330

    Capsules

    56 X 100 mg

    partial basket chart

    Capsules

    56 X 150 mg

    partial basket chart 58334

    Capsules

    56 X 200 mg

    partial basket chart

    Capsules

    56 X225 mg

    partial basket chart

    Capsules

    56 X 300 mg

    partial basket chart 58335

    Related information


    Dosage

    The dose range is 150 to 600 mg per day given in either two or three divided doses.
    Neuropathic pain: Pregabalin treatment can be started at a dose of 150 mg per day given as two or three divided doses. Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after an interval of 3 to 7 days, and if needed, to a maximum dose of 600 mg per day after an additional 7-day interval.
    Fibromyalgia: The usual dose of Pregabalin Dexcel for most fibromyalgia patients is 300 to 450 mg/day given in two divided doses. Some patients may derive additional benefit at 600 mg per day. Dosing should begin at 75 mg two times a day (150 mg/day) and may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Patients who do not experience sufficient benefit with 300 mg/day may be further increased to 225 mg two times a day (450 mg/day). If needed, in some patients, based on individual response and tolerability, the dose may be increased to maximum dosage of 600 mg/day after an additional week.
    Discontinuation of pregabalin: In accordance with current clinical practice, if pregabalin has to be discontinued, it is recommended this should be done gradually over a minimum of 1 week independent of the indication.
    Renal impairment: Pregabalin is eliminated from the systemic circulation primarily by renal excretion as unchanged drug. As pregabalin clearance is directly proportional to creatinine clearance, dose reduction in patients with compromised renal function must be individualized according to creatinine clearance. Pregabalin is removed effectively from plasma by haemodialysis (50% of drug in 4 hours). For patients receiving haemodialysis, the pregabalin daily dose should be adjusted based on renal function. In addition to the daily dose, a supplementary dose should be given immediately following every 4-hour haemodialysis treatment.
    Hepatic impairment: No dosage adjustment is required for patients with hepatic impairment.
    Paediatric population: The safety and efficacy of Pregabalin in children below the age of 12 years and in adolescents (12-17 years of age) have not been established. No recommendation on a posology can be made.
    Elderly: Elderly patients may require a dose reduction of pregabalin due to a decreased renal function.
    Please refer to the license holder for further details.


    Indications

    Treatment of peripheral and central neuropathic pain in adults. Management of  Fibromyalgia.


    Contra-Indications

    Please refer to the license holder for further details.


    Special Precautions

    Please refer to the license holder for further details.


    Side Effects

    Please refer to the license holder for further details.


    Drug interactions

    Please refer to the license holder for further details.


    Pregnancy and Lactation

    Please refer to the license holder for further details.


    Overdose

    Please refer to the license holder for further details.


    Important notes

    Please refer to the license holder for further details.


    Manufacturer
    Dexcel Ltd.
    Licence holder
    CLOSE